Cyclotrons are currently used for the preparation of a wide variety of radionuclides that have applications in single photon emission computed tomography (SPECT) and positron emission tomography (PET). Consequently, there is high demand from IAEA Member States for support in the area of radiopharmaceutical production using cyclotron produced radioisotopes. This publication describes the potential radionuclide production routes using cyclotrons in different energy ranges and provides methods for the development of targets and provides details of the chemistry for the separation of radionuclides from target materials. The readership of this publication includes scientists, operators interested in putting this technology into practice, technologists already working with cyclotrons who wish to enhance the utility of existing machines, and managers in the process of setting up radionuclide facilities in their countries. Students working towards higher level degrees in related fields may also benefit from this publication.

Therapeutic radiopharmaceuticals play a major role in today's nuclear medicine with a positive impact on the diagnosis and treatment of diseases. One area of application is radiation synovectomy (RSV). Previously, RSV agents were often simple colloids. More recently, matrixes labelled with short/medium range beta emitters have been developed. However, the lack of generic and peer-reviewed production, quality control as well as clinical application guidelines and recommendations, are a major concern for their application in patients. This publication presents recommendations and suggestions for production, quality control and quality assurance procedures for Member State laboratories in charge of radiopharmaceutical production, with a focus on the latest RSV agents. It also proposes standard operating procedures for RSV application in patients. The publication aims to assist both newcomers and those currently working in the field in establishing comparable levels of control.

The fifth edition of this respected book encompasses all the advances and changes that have been made since it was last revised. It not only presents new ideas and information, it shifts its emphases to accurately reflect the inevitably changing perspectives in the field engendered by progress in the understanding of radiological physics. The rapid development of computing technology in the three decades since the publication of the fourth edition has enabled the equally rapid expansion of radiology, radiation oncology, nuclear medicine and radiobiology. The understanding of these clinical disciplines is dependent on an appreciation of the underlying physics. The basic radiation physics of relevance to clinical oncology, radiology and nuclear medicine has undergone little change over the last 70 years, so much of the material in the introductory chapters retains the essential flavour of the fourth edition, updated as required. This book is written to help the practitioners in these fields understand the physical science, as well as to serve as a basic tool for physics students who intend working as medical radiation physicists in these clinical fields. It is the authors’ hope that students and practitioners alike will find the fifth edition of The Physics of Radiology lucid and straightforward.

This book covers foundational topics in the emerging field of radiopharmaceutical therapy. It is divided into three sections: fundamentals, deeper dives, and special topics. In the first section, the authors examine the field from a bird’s-eye view, covering topics including the history of radiopharmaceutical therapy, the radiobiology of radiopharmaceutical therapy, and the radiopharmaceutical chemistry of both metallic and non-metallic radionuclides. The second section provides a more in-depth look at specific radiotherapeutics. Chapters include broader discussions of the different platforms for radiopharmaceutical therapy as well as more focused case studies covering individual radiotherapeutics. The third and final section explores a number of areas for further study, including medical physics, artificial intelligence, in vivo pretargeting, theranostic imaging, and the regulatory review process for radiotherapeutics. This book is the first of its kind and is useful for a broad audience of scientists, researchers, physicians, and students across a range of fields, including biochemistry, cancer biology, nuclear medicine, radiology, and radiation oncology.

Currently an estimated 17 million nuclear medicine procedures are performed each year in the US and constantly evolving, as new radiopharmaceuticals and imaging techniques are introduced for better diagnosis and treatment of human diseases. In keeping up with new developments, the Seventh Edition of Fundamentals of Nuclear Pharmacy chronicles the advancements in radiopharmaceuticals and their use in clinical applications. It discusses basic concepts such as the atom, radioactive decay, instrumentation and production of radionuclides, and explores the design, labeling, characteristics and quality control of radiopharmaceuticals. Radiation regulations and diagnostic and therapeutic applications of radiopharmaceuticals are detailed. Thoroughly updated, the Seventh Edition includes new topics such as alternative productions of 99Mo; production of 64Cu, 86Y, 89Zr, 177Lu, 223Ra; synthesis and clinical uses of new radiopharmaceuticals such as DaTscan, Xofigo, Amyvid, Neuraceq, Vizamyl, Axumin and 68Ga-DOTATATE; dosimetry of new radiopharmaceuticals; theranostic agents and translational medicine. It features numerous examples, diagrams, and images to further clarify the information and offers end- of-chapter questions to help readers assess their comprehension of the material. Recognized as a classic text on nuclear chemistry and pharmacy and acclaimed for its concise and easy-to-understand presentation, Fundamentals of Nuclear Pharmacy is an authoritative resource for nuclear medicine physicians, residents, students, and technologists.

This book provides detailed information on therapeutic radiopharmaceuticals and discusses emerging technologies which have potential for broad clinical implementation. Recent advances in molecular biology, radiopharmaceutical chemistry and radioisotope production have stimulated a new era for the use of radiopharmaceuticals for targeted radionuclide therapy (TRT). Emerging clinical trials include use of peptides and monoclonal antibodies radiolabeled with therapeutic radionuclides for cancer therapy. In addition, small molecules are used for the treatment of chronic diseases such as metastatic bone pain palliation and radiation synovectomy of inflammatory joints. In the interventional arena, therapy of primary and metastatic liver cancer and arterial restenosis following angioplasty of both the coronary and peripheral arteries are being explored. Reactor and accelerator production of therapeutic radioisotopes is also integrated into these discussions. The development and use of radiopharmaceutical targeting characteristics required for treatment of specific disease processes and how these are implemented for radiopharmaceutical design strategies are also described. Radiopharmaceuticals for Therapy will benefit audiences in nuclear medicine and radionuclide therapy and will thus prove an invaluable source of up-to-date information for students, radiopharmaceutical scientists and professionals working in the radiopharmacy and nuclear medicine specialties.